Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Arkansas
University of Arkansas
Intergroupe Francophone du Myelome
Janssen Scientific Affairs, LLC
Fudan University
Canadian Cancer Trials Group
National Heart, Lung, and Blood Institute (NHLBI)
European Society for Blood and Marrow Transplantation
Sun Yat-sen University
National Cancer Institute (NCI)
Celgene
Celgene
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Gruppo Italiano per lo Studio del Mieloma Multiplo
University of Leeds
University of Leeds
Grupo de Estudos Multicentricos em Onco-Hematologia
Jinling Hospital, China
Nanfang Hospital, Southern Medical University
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
China Medical University, China
The First People's Hospital of Hefei
University of Arkansas
Nantes University Hospital
University of Arkansas
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Norwegian University of Science and Technology
National Cancer Institute (NCI)
Erkim Ilac A.S.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Mayo Clinic
University College, London
Grupo de Estudos Multicentricos em Onco-Hematologia
PETHEMA Foundation
University of Arkansas
Fudan University
Grupo de Estudos Multicentricos em Onco-Hematologia
Nordic Myeloma Study Group
University of Arkansas
University Hospital, Caen
PETHEMA Foundation
National Cancer Institute (NCI)
Central Hospital, Nancy, France
Università Politecnica delle Marche
University Hospital, Lille